| Name | Title | Contact Details |
|---|
Offering the benefits of resort-style amenities and an independent lifestyle, with access to award-winning lifecare services providing added peace of mind.
Bayside Manor is a Keansburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Webster is a town in the northeast corner of Monroe County, New York, United States.
Windsor Health Plan, Inc. is a Medicare Advantage plan with a Medicare contract, and a Medicare-approved Part D Sponsor, whose core purpose is to improve health and well being, peace of mind and financial security for our members when navigating health care coverage options. A partnership between Windsor Health Plan and Sterling Life Insurance Company since 2011, the organization can now provide more resources, member support and plan options for Medicare Advantage beneficiaries and is a leader in the provision of health care to Medicare- and Medicaid-eligible members seeking to enhance their quality of life. Windsor Health Plan manages government sponsored health plans and provides specialty managed care services to insurance providers and to health care providers. Windsor Health Plan is a division of Windsor Health Group, with corporate offices in Atlanta and operational offices in Nashville, Tenn. and Bellingham, Wash., as well as regional offices throughout the United States.
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III